BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21317715)

  • 21. Nuclear Brachyury Expression Is Consistent in Chordoma, Common in Germ Cell Tumors and Small Cell Carcinomas, and Rare in Other Carcinomas and Sarcomas: An Immunohistochemical Study of 5229 Cases.
    Miettinen M; Wang Z; Lasota J; Heery C; Schlom J; Palena C
    Am J Surg Pathol; 2015 Oct; 39(10):1305-12. PubMed ID: 26099010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.
    Schelling LA; Williamson SR; Zhang S; Yao JL; Wang M; Huang J; Montironi R; Lopez-Beltran A; Emerson RE; Idrees MT; Osunkoya AO; Man YG; Maclennan GT; Baldridge LA; Compérat E; Cheng L
    Hum Pathol; 2013 Oct; 44(10):2227-33. PubMed ID: 23850495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies.
    Yaskiv O; Zhang X; Simmerman K; Daly T; He H; Falzarano S; Chen L; Magi-Galluzzi C; Zhou M
    Am J Surg Pathol; 2011 Jul; 35(7):1062-8. PubMed ID: 21623182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical evaluation of ERG expression in various benign and malignant tissues.
    Liu H; Shi J; Wilkerson M; Yang XJ; Lin F
    Ann Clin Lab Sci; 2013; 43(1):3-9. PubMed ID: 23462600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of ERG versus AMACR expression in diagnosis of minimal adenocarcinoma of the prostate in needle biopsy tissue.
    Andrews C; Humphrey PA
    Am J Surg Pathol; 2014 Jul; 38(7):1007-12. PubMed ID: 24705308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors.
    Partanen TA; Alitalo K; Miettinen M
    Cancer; 1999 Dec; 86(11):2406-12. PubMed ID: 10590384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.
    Fontugne J; Davis K; Palanisamy N; Udager A; Mehra R; McDaniel AS; Siddiqui J; Rubin MA; Mosquera JM; Tomlins SA
    Mod Pathol; 2016 Feb; 29(2):157-65. PubMed ID: 26743468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distribution of keratins in normal endothelial cells and a spectrum of vascular tumors: implications in tumor diagnosis.
    Miettinen M; Fetsch JF
    Hum Pathol; 2000 Sep; 31(9):1062-7. PubMed ID: 11014572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.
    Miettinen M; McCue PA; Sarlomo-Rikala M; Rys J; Czapiewski P; Wazny K; Langfort R; Waloszczyk P; Biernat W; Lasota J; Wang Z
    Am J Surg Pathol; 2014 Jan; 38(1):13-22. PubMed ID: 24145643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunoreactivity using anti-ERG monoclonal antibodies in sarcomas is influenced by clone selection.
    Machado I; Mayordomo-Aranda E; Scotlandi K; Picci P; Llombart-Bosch A
    Pathol Res Pract; 2014 Aug; 210(8):508-13. PubMed ID: 24906228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.
    Torres A; Alshalalfa M; Davicioni E; Gupta A; Yegnasubramanian S; Wheelan SJ; Epstein JI; De Marzo AM; Lotan TL
    Prostate; 2018 Sep; 78(12):896-904. PubMed ID: 29761525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis.
    Parsons JK; Gage WR; Nelson WG; De Marzo AM
    Urology; 2001 Oct; 58(4):619-24. PubMed ID: 11597556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.
    Furusato B; Tan SH; Young D; Dobi A; Sun C; Mohamed AA; Thangapazham R; Chen Y; McMaster G; Sreenath T; Petrovics G; McLeod DG; Srivastava S; Sesterhenn IA
    Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):228-37. PubMed ID: 20585344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ERG Immunoreactivity in Blastic Hematolymphoid Neoplasms: Diagnostic Pitfall in the Workup of Undifferentiated Malignant Neoplasms.
    Koo M; Natkunam Y
    Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):42-48. PubMed ID: 34261976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
    Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
    Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current State of ERG as Biomarker in Prostatic Adenocarcinoma.
    Acs B; Szarvas T; Szekely N; Nyirady P; Szasz AM
    Curr Cancer Drug Targets; 2015; 15(8):643-51. PubMed ID: 26452381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.
    Morais CL; Herawi M; Toubaji A; Albadine R; Hicks J; Netto GJ; De Marzo AM; Epstein JI; Lotan TL
    Prostate; 2015 Oct; 75(14):1610-9. PubMed ID: 26178158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
    Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
    Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".
    He H; Magi-Galluzzi C; Li J; Carver P; Falzarano S; Smith K; Rubin MA; Zhou M
    Am J Surg Pathol; 2011 Apr; 35(4):608-14. PubMed ID: 21383613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.